Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics, Inc. (ELTX)
Company Research
Source: GlobeNewswire
BOSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on October 15, 2024, Elicio granted an aggregate of 5,900 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan. Each grant provides for the purchase of shares of Elicio common stock at a price of $4.49 per share, the closing price per share of Elicio common stock as reported by Nasdaq on October 15, 2024, the date of grant. The grants vest over four years, with 25 percent of the shares vesting on the first anniversary
Show less
Read more
Impact Snapshot
Event Time:
ELTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELTX alerts
High impacting Elicio Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ELTX
News
- Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 [Yahoo! Finance]Yahoo! Finance
- Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024GlobeNewswire
- Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment [Yahoo! Finance]Yahoo! Finance
- Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study EnrollmentGlobeNewswire
- Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswire
ELTX
Sec Filings
- 12/18/24 - Form 4
- 12/12/24 - Form 8-K
- 12/3/24 - Form 8-K
- ELTX's page on the SEC website